Prothena/$PRTA
1D1W1MYTD1Y5YMAX
Capital at risk
About Prothena
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.
- Ticker
- $PRTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 67
- Headquarters
- Dublin, Ireland
- Website
- www.prothena.com
Prothena Metrics
BasicAdvanced
$427M
-
-$0.83
-0.35
-
Price and volume
Market cap
$427M
Beta
-0.35
52-week high
$11.80
52-week low
$7.73
Average daily volume
398K
Financial strength
Current ratio
25.048
Quick ratio
24.721
Long term debt to equity
0.014
Total debt to equity
0.024
Profitability
EBITDA (TTM)
-59.04
Gross margin (TTM)
-19.11%
Net profit margin (TTM)
-80.67%
Operating margin (TTM)
-109.79%
Effective tax rate (TTM)
0.81%
Revenue per employee (TTM)
$810,000
Management effectiveness
Return on assets (TTM)
-10.67%
Return on equity (TTM)
-14.39%
Valuation
Price to revenue (TTM)
8.144
Price to book
1.5
Price to tangible book (TTM)
1.5
Price to free cash flow (TTM)
-7.315
Free cash flow yield (TTM)
-13.67%
Free cash flow per share (TTM)
-1.137
Growth
Revenue change (TTM)
427.32%
Earnings per share change (TTM)
-85.19%
3-year revenue growth (CAGR)
-1.83%
10-year revenue growth (CAGR)
44.93%
3-year earnings per share growth (CAGR)
-33.19%
10-year earnings per share growth (CAGR)
-13.37%
What the Analysts think about Prothena
Analyst ratings (Buy, Hold, Sell) for Prothena stock.
Analyst projections of the future price of Prothena stock.
Bulls say / Bears say
Coramitug has reached Phase 3 in ATTR-CM, received FDA Fast Track designation and generated a $50 million milestone payment after Phase 3 enrolment. Its Phase 2 data showed a meaningful NT-proBNP improvement and better echocardiographic measures, giving the programme clinical and regulatory momentum. (Business Wire, Prothena)
Newly published PADOVA results provided exploratory clinical and biomarker signals that prasinezumab may slow progression in early Parkinson’s disease, while longer-term extension data showed a sustained effect. Roche has taken the asset into the Phase 3 PARAISO trial, creating a potentially valuable disease-modifying opportunity. (ScienceDirect, Prothena)
Prothena’s partnered model limits the need to fund every late-stage trial itself: management says partnered programmes could generate roughly $3 billion of future milestones plus royalties. The company also reported $289.1 million of cash and restricted cash at the end of June, with expected 2026 net cash use of only $18 million to $23 million. (Prothena, BioSpace)
The prasinezumab evidence is not conclusive: the earlier PASADENA study missed its primary endpoint, and the Lancet paper describes PADOVA’s benefit as a possibility based on supportive exploratory signals. The Phase 3 PARAISO trial therefore remains a high-risk test rather than a confirmation. (ScienceDirect)
Prothena still has no marketed product to provide recurring revenue. Second-quarter revenue was about $1 million against an $18.6 million loss, showing how sharply results can weaken when collaboration milestones do not arrive in the period. (Simply Wall St, Prothena)
The main value drivers remain years from decisive readouts: Roche’s prasinezumab and Novo Nordisk’s coramitug Phase 3 trials both expect primary completion in 2029, while BMS’s Alzheimer’s trial is due in the first half of 2027. Prothena also depends on partners to choose whether to advance programmes such as PRX019, leaving timing and execution largely outside its control. (Prothena, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2026.
Prothena Financial Performance
Revenues and expenses
Prothena Earnings Performance
Company profitability
Upcoming events
No upcoming events
Prothena News
AllArticlesVideos
Funds containing Prothena
AllUSDEURGBP
Fund name | Fund size | $PRTA weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.04% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.04% |
iShares Healthcare Innovation£DRDR | £1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.03% |
iShares Ageing Population€AGED | €822M | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.